Consensus Biogen Inc.

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 13/02/2026 GMT			5-day change	1st Jan Change
196.52 ^USD	+0.52%		-2.32%	+11.67%

02-13	Biogen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-13-2026 10:30 AM
02-12	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…

Evolution of the Average Target: Biogen Inc.

Evolution of the Target Price: Biogen Inc.

Changes in Analyst Recommendations: Biogen Inc.

2144a5f135493a44c7c.MttOIUmujgxuSm7yWN3dSB72UDbkLzqF2PfwPaDQ27o.BLJ8EXz_52BZAQe-OuunDnnBAkOjQXDBlZCSepOPt_dLiBRvMIPYfhcVIw~29a1217ee4f88cb9057f8f7f767d6fd1

Analysts' recommendations: Biogen Inc.

02-12	Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap…
02-10	Mizuho Raises Price Target on Biogen to $236 From $207, Keeps Outperform Rating	MT
02-09	Biogen Sales Execution, Growth Support Long-Term EPS, RBC Says	MT
02-09	Wedbush Raises Price Target on Biogen to $187 From $178, Keeps Neutral Rating	MT
02-09	HC Wainwright Adjusts Price Target on Biogen to $228 From $194, Maintains Buy Rating	MT
02-09	RBC Raises Price Target on Biogen to $233 From $217, Keeps Outperform Rating	MT
02-09	Morgan Stanley Raises Price Target on Biogen to $190 From $156, Keeps Equalweight Rating	MT
02-09	Bernstein Adjusts Price Target on Biogen to $201 From $191, Maintains Market Perform Rating	MT
02-09	Piper Sandler Adjusts Price Target on Biogen to $177 From $157, Maintains Neutral Rating	MT
02-09	Citigroup Adjusts Price Target on Biogen to $215 From $185, Maintains Neutral Rating	MT
02-09	Guggenheim Adjusts Price Target on Biogen to $246 From $185, Maintains Buy Rating	MT
02-09	TD Cowen Adjusts Price Target on Biogen to $215 From $175, Maintains Buy Rating	MT
02-09	Analyst recommendations: Align, Take-Two, Biogen, PayPal, Stellantis…
02-06	Stifel Nicolaus Adjusts Biogen PT to $214 From $202, Maintains Buy Rating	MT
02-03	Bernstein Adjusts Biogen Price Target to $191 From $197	MT
01-30	Oppenheimer Adjusts Biogen Price Target to $225 From $205, Maintains Outperform Rating	MT
01-30	Oppenheimer Raises Price Target on Biogen to $225 From $205, Keeps Outperform Rating	MT
01-27	Citigroup Adjusts Price Target on Biogen to $185 From $180, Maintains Neutral Rating	MT
01-23	Wedbush Raises Price Target on Biogen to $178 From $143, Keeps Neutral Rating	MT
01-20	RBC Trims Price Target on Biogen to $217 From $220, Keeps Outperform Rating	MT
01-09	Bernstein Adjusts Price Target on Biogen to $197 From $157, Maintains Market Perform Rating	MT
01-08	Goldman Sachs Adjusts Price Target on Biogen to $225 From $197, Maintains Buy Rating	MT
01-08	Mizuho Raises Price Target on Biogen to $207 From $177, Keeps Outperform Rating	MT
01-08	RBC Raises Price Target on Biogen to $220 From $210, Keeps Outperform Rating	MT
01-07	UBS Adjusts Price Target on Biogen to $185 From $130, Maintains Neutral Rating	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

196.52USD

Average target price

205.52USD

Spread / Average Target

+4.58%

High Price Target

260.00USD

Spread / Highest target

+32.30%

Low Price Target

143.00USD

Spread / Lowest Target

-27.23%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Mizuho Securities
Wedbush
TD Cowen
Guggenheim
Citigroup
Piper Sandler
Bernstein
Morgan Stanley
RBC Capital Markets
HC Wainwright
Stifel Nicolaus
Oppenheimer
Goldman Sachs
UBS
BMO Capital
Wells Fargo Securities
HSBC
Jefferies & Co.
Baird
Rothschild & Co Redburn
Canaccord Genuity
Truist Securities
Argus
Scotiabank
JPMorgan Chase
Redburn Atlantic
BofA Securities
Leerink Partners
Needham & Co.
Barclays
Raymond James
Atlantic Equities
Cowen
SVB Securities LLC
SVB Leerink
Cantor Fitzgerald
William Blair & Co.
Credit Suisse
DZ Bank